Avatrombopag usage and dosage guide, what key points patients need to know

Avatrombopag is an oral thrombopoietin receptor agonist (TPO-RA) that is commonly used to treat two types of patients: one is people with chronic liver disease (CLD) who need to undergo invasive surgery but are at risk of thrombocytopenia; the other is patients with chronic immune thrombocytopenia (ITP). Different indications correspond to different medication regimens, so patients must conduct an individualized assessment based on the doctor's recommendations before taking medication.

For patients with chronic liver disease-related thrombocytopenia, the recommended usage regimen of avatrombopag is: start taking the drug 10-13 days before surgery, once a day for 5 consecutive days. The dosage is divided into two types based on the baseline platelet count: if the baseline platelet count is 40–<50×10⁹/L, the recommended daily dose is 40mg; if the baseline is lower than 40×10⁹/L, the recommended dose is 60mg daily. The 10th to 13th day after the end of medication is usually the best time window for operation, because platelets are at their peak at this time.

For ITP patients, the starting dose is usually 20 mg daily. The goal of treatment is to maintain platelets within a safe range of >50×10⁹/L and reduce the risk of bleeding. Some patients may experience results early in treatment, but dose adjustments still need to be made based on individual response. The maximum daily dose should not exceed 40 mg to reduce the risk of thrombotic events.

It is worth noting that avatrombopag needs to be swallowed whole, and it is not recommended to break or chew it. It can be taken before or after meals, but it should be taken at the same time every day. In addition, since the drug is metabolized by the liver, it is recommended to regularly monitor liver function and blood routine indicators. Patients should not change dosage or discontinue medication, especially without medical evaluation.

Compared with otherTPO-RAs (such as Eltrombopag, Romiplostim), one of the advantages of avatrombopag is that it has high oral bioavailability and does not require dietary restrictions, which is especially convenient for ITP patients who take medicine for a long time. At the same time, it does not contain heavy metal chelating properties, avoiding interactions with certain minerals such as calcium, iron, etc.

Reference materials:https://go.drugbank.com/drugs/DB11995